About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company (LLY) is a Healthcare company in the Drug Manufacturers - General industry with a market capitalisation of $994.9B. The stock trades at 37.45x trailing earnings and yields 0.62%.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $994.9B
- P/E ratio
- 37.45
- Forward P/E
- 23.62
- EPS (TTM)
- $29.79
- Revenue (TTM)
- $79.7B
- Free cash flow
- $11.1B
- Profit margin
- 33.5%
- Dividend yield
- 0.62%
- Beta
- 0.50
- Shares outstanding
- 891.7M
Financial health: Strong8.3/10
7 strengths, 1 concern. Weakest points: debt to equity.
- Debt to equity: 1.60 (Concern, benchmark < 0.5) — Debt of 1.60x equity is high against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Current ratio: 1.58 (Strong, benchmark > 1.5) — Short-term assets cover 1.58x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 102.3% (Strong, benchmark > 15%) — Earns 102.3% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 83.4% (Strong, benchmark > 40%) — Keeps 83.4% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 33.5% (Strong, benchmark > 10%) — Turns 33.5% of revenue into profit, comfortably past the > 10% mark.
- Revenue growth: 47.7% (Strong, benchmark > 10%) — Revenue changed 47.7% year on year, comfortably past the > 10% mark.
- Earnings growth: 26.2% (Strong, benchmark > 10%) — Earnings changed 26.2% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.10 (Watch, benchmark < 1) — At 1.10, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 21.7% (Strong, benchmark < 60%) — Pays out 21.7% of earnings as dividends, leaving room to keep paying.